Search

Your search keyword '"Agrati, Chiara"' showing total 694 results

Search Constraints

Start Over You searched for: Author "Agrati, Chiara" Remove constraint Author: "Agrati, Chiara"
694 results on '"Agrati, Chiara"'

Search Results

1. Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study

2. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study

3. Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications

4. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)

5. Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study

7. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study

9. Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results

10. Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

11. Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation

12. Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine

13. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital

17. 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation

18. Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

19. Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV

20. In Vitro and In Vivo Crosstalk between Type I IFN and IL-8 Responses in SARS-CoV-2 Infection

21. Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine

22. Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in PLWH

23. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)

24. Multi-omics approach to COVID-19: a domain-based literature review

31. Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications

32. P1461: INFLAMMATORY AND SENESCENCE-ASSOCIATED MEDIATORS AFFECT THE PERSISTENCE OF HUMORAL RESPONSE TO COVID-19 MRNA VACCINATION IN TRANSFUSION-DEPENDENT BETA-THALASSEMIC PATIENTS

34. Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome

36. Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters

37. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose

38. SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel

39. Third dose of SARS‐CoV2 mRNA vaccination produces robust persistent cellular and humoral immune responses in liver transplant recipients

44. Inflammatory and senescence‐associated mediators affect the persistence of humoral response to COVID ‐19 mRNA vaccination in transfusion‐dependent beta‐thalassemic patients

46. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)

47. SARS-CoV-2 infection of thymus induces loss of function that correlates with disease severity

48. Immunogenicity and Reactogenicity of Modified Vaccinia Ankara Pre-Exposure Vaccination Against Mpox According to Previous Smallpox Vaccine Exposure

49. The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age

50. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies

Catalog

Books, media, physical & digital resources